The role of rifaximin therapy in patients with irritable bowel syndrome without constipation

References

• Pimentel M, Lembo T, Chey WD et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N. Engl. J. Med.364, 22–32 (2011).
   PubMed Web of Science ®Google Scholar
• Drossman DA. AGA technical review on irritable bowel syndrome. Gastroenterology123(6), 2108–2131 (2002).
   PubMed Web of Science ®Google Scholar
• Camilleri M, Andresen V. Current and novel therapeutic options for irritable bowel syndrome management. Dig. Liver Dis.41, 854–862 (2009).
   PubMedGoogle Scholar
• Layer P, Andresen V. Review article: rifaximin, a minimally absorbed oral antibacterial, for the treatment of travellers’ diarrhoea. Aliment. Pharmacol. Ther.31, 1155–1164 (2010).
   PubMedGoogle Scholar
• Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am. J. Gastroenterol.98, 412–419 (2003).
   PubMed Web of Science ®Google Scholar
• Spiegel BM. Questioning the bacterial overgrowth hypothesis of IBS: an epidemiologic and evolutionary perspective. Clin. Gastroenterol. Hepatol.6, 461–469 (2011).
   Google Scholar
• Yu D, Cheeseman F, Vanner S. Combined oro–caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro–caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut60(3), 334–340 (2011).
   PubMed Web of Science ®Google Scholar
• Reddymasu SC, Sostarich S, McCallum RW. Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors? BMC Gastroenterol.10, 23 (2010).
   PubMed Web of Science ®Google Scholar
• Debbia EA, Maioli E, Roveta S, Marchese A. Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations. J. Chemother.20(2), 186–194 (2008).
   PubMed Web of Science ®Google Scholar
• Pimentel M. Review of rifaximin as treatment for SIBO and IBS. Expert Opin. Investig. Drugs.18(3), 349–358 (2009).
   PubMed Web of Science ®Google Scholar
• Chang JY, Talley NJ. Current and emerging therapies in irritable bowel syndrome: from pathophysiology to treatment Trends Pharmacol. Sci.31(7), 326–334 (2010).
   PubMedGoogle Scholar
• Layer P, Andresen V. Review article: rifaximin, a minimally absorbed oral antibacterial, for the treatment of travellers’ diarrhoea. Aliment. Pharmacol. Ther.31, 1155–1164 (2010).
   PubMedGoogle Scholar
• Posserud I, Stotzer, PO, Bjornsson, ES et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut56, 802–808 (2007).
   PubMed Web of Science ®Google Scholar
• Shah ED, Basseri RJ, Chong K, Pimentel M. Abnormal breath testing in IBS: a meta- analysis. Dig. Dis. Sci.55(9), 2441–2449 (2010).
   PubMed Web of Science ®Google Scholar
• Choung RS, Ruff KC, Malhotra A et al.Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment. Pharmacol. Ther.33(9), 1059–1067 (2011).
   PubMed Web of Science ®Google Scholar
• Attar A, Flourie B, Rambaud J-C, Franchisseur C, Ruszniewski P, Bouhnik Y. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology117, 794–797 (1999).
   PubMed Web of Science ®Google Scholar
• Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann. Intern. Med.145, 557–563 (2006).
   PubMed Web of Science ®Google Scholar
• Peralta S, Cottone C, Doveri T, Almasio PL, Craxi A. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with rifaximin. World J. Gastroenterol.15(21), 2628–2631 (2009).
   PubMed Web of Science ®Google Scholar
• Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am. J. Gastroenterol.104(4), 1033–1049 (2009).
   PubMed Web of Science ®Google Scholar
• Søndergaard B, Olsson J, Ohlson K, Svensson U, Bytzer P, Ekesbo R. Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: A randomized, placebo-controlled trial. Scand. J. Gastroenterol.46(6), 663–672 (2011).
   PubMed Web of Science ®Google Scholar
• Bardhan KD, Bodemar G, Geldof H et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther.14, 23–34 (2000).
   PubMed Web of Science ®Google Scholar
• Camilleri M, Chey WY, Mayer EA et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch. Intern. Med.161, 1733–1740 (2001).
   PubMed Web of Science ®Google Scholar
• Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut58, 367–378 (2009).
   PubMed Web of Science ®Google Scholar
• Ford AC, Talley NJ, Spiegel BM et al. Effect of fiber, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ337, a2313 (2008).
   PubMed Web of Science ®Google Scholar